EN DE

OUE LIPPO HEALTHCARE LTD (5WA) Fair Value & Analysis

Healthcare · SG · Market cap 173M SGD

OL OUE LIPPO HEALTHCARE LTD 5WA · SG
Price0.0390 SGD
Fair Value0.0862 SGD
Upside+121.0%
Quality53/100
Watch OUE LIPPO HEALTHCARE LTD for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -11.1% net margin
Moderate debt · generates free cash flow
Mixed vs. peers (7/13)
Narrow moat 41/100
Evidence: Medium Range 0.0589 SGD – 0.1096 SGD Share as image

Fair value as of: Aug 13, 2026

From 14 valuation models · updated 4 days ago

Fair value updated Aug 13, 2026, revised from 0.0898 SGD to 0.0862 SGD (−4.0%) since Aug 9, 2026. Share price +30.0% over the past month.

A solid business, screening 121% undervalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The price is below even our cautious bear case (0.0589 SGD). The market is more pessimistic than our downside scenario.
  • Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (0.0589 SGD to 0.1096 SGD) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

0.0440 SGD 0.0190 SGD Fair Value 0.0862 SGD May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 0.0190 SGD – 0.0440 SGD · fair‑value band 0.0589 SGD – 0.1096 SGD · the 0.0390 SGD price screens below the 0.0862 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

OUE LIPPO HEALTHCARE LTD (5WA) currently trades at 0.0390 SGD, while our model-based Fair Value estimate is 0.0862 SGD, implying the stock looks roughly 121.0% undervalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, OUE LIPPO HEALTHCARE LTD generated revenue of 152M SGD at a net margin of -11.1%. Revenue grew 2.5% year over year. It earns a return on equity of 1.2%. Net debt stands at 465M SGD. Fundamentals as of Aug 13, 2026

Our scenario range runs from 0.0589 SGD (bear case) to 0.1096 SGD (bull case); at 0.0390 SGD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 77% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 121%, 5WA screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 0.0800 SGD 0.1500 SGD 0.2800 SGD 80
Rev-Margin DCF 0.0600 SGD 0.1300 SGD 0.2900 SGD 74
ROIC Compounder 0.0500 SGD 0.0800 SGD 0.1000 SGD 72
All 14 models by family
DCF Models
FCF DCF 0.0900 SGD 0.1500 SGD 0.3000 SGD 38
5Y Revenue Exit 0.0500 SGD 0.1100 SGD 0.2300 SGD 39
5Y EBITDA Exit 0.1300 SGD 0.2600 SGD 0.5300 SGD 41
10Y Revenue Exit 0.0600 SGD 0.1600 SGD 0.2200 SGD 36
10Y EBITDA Exit 0.1100 SGD 0.3000 SGD 0.6300 SGD 37
Earnings-Based
EPV 0.0500 SGD 0.0700 SGD 0.0800 SGD 59
Dividend Discount
Gordon GGM 0.0100 SGD 70
Multiples
EV/EBIT 0.1800 SGD 0.2600 SGD 0.3300 SGD 53
EV/EBITDA 0.1500 SGD 0.2100 SGD 0.2800 SGD 54
EV/Revenue 0.0300 SGD 0.0600 SGD 0.0900 SGD 43
Asset-Based
NCAV (Graham) 0.0300 SGD 0.0400 SGD 0.0600 SGD 50
Growth DCF
Growth DCF 0.0800 SGD 0.1500 SGD 0.2800 SGD 80
Rev-Margin DCF 0.0600 SGD 0.1300 SGD 0.2900 SGD 74
Economic Profit
ROIC Compounder 0.0500 SGD 0.0800 SGD 0.1000 SGD 72

Widest divergence: Multiples (0.2100 SGD) versus Asset-Based (0.0400 SGD). Highest evidence: Growth DCF (80).

Notify me when 5WA reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 152M SGD
Revenue growth (YoY) +2.5%
Net margin -11.1%
Return on equity 1.2%
Free cash flow 51.1M SGD FY2025
Operating margin 49.4%
More key figures
EPS growth (YoY) -75.0%
Net debt 465M SGD FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 53/100

Of which business quality 50 · Market factors (momentum, volatility) 75

Profitability 6
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 98
Earnings quality: real cash, not paper profit
Fin. Strength 12
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 89
Price trend over the last 3–12 months (market factor)
52W Momentum 81
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

OUE Healthcare Limited, an investment holding company, owns, operates, and invests in healthcare businesses in Singapore, China, Myanmar, Indonesia, and Japan. It operates through Healthcare Operations, Healthcare Assets, Properties Under Development, and Investments segments.

Full company description

OUE Healthcare Limited, an investment holding company, owns, operates, and invests in healthcare businesses in Singapore, China, Myanmar, Indonesia, and Japan. It operates through Healthcare Operations, Healthcare Assets, Properties Under Development, and Investments segments. The company is involved in the operation of hospitals and clinics; supply of medical equipment and pharmaceutical products; and rental of investment properties and owned assets. It also engages in the development of medical facilities, healthcare-related assets, and integrated mixed-used projects; and investment in real estate investment trusts and properties. The company was formerly known as OUE Lippo Healthcare Limited and changed its name to OUE Healthcare Limited in April 2023. The company was founded in 2010 and is headquartered in Singapore. OUE Healthcare Limited is a subsidiary of OUE Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

OUE LIPPO HEALTHCARE LTD reported revenue of 152M SGD in FY2025 versus 19.7M SGD in FY2021, a compound +66.8%/yr. Reported net income was −16.9M SGD in FY2025.

Growth Quality 67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
152M SGD
Latest YoY
+1.4%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.4%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+50.1%
Avg. growth/yr (12Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.1%
Revenue +66.8%/yr
FY21 19.7M SGD
FY22 120M SGD
FY23 159M SGD
FY24 150M SGD
FY25 152M SGD
Net income
FY21 111M SGD
FY22 4.4M SGD
FY23 8.0M SGD
FY24 −6.0M SGD
FY25 −16.9M SGD

Watch 5WA: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "OUE LIPPO HEALTHCARE LTD Fair Value". https://www.fairvalue-calculator.com/stock/5WA

Peer Group

Medical Care Facilities · 267 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 53 · Below median
Fair Value upside +131% · Top 25%
Return on equity (TTM) 1% · Below median
Return on assets 4% · Above median
Net margin (TTM) -11% · Bottom 25%
Operating margin (TTM) 49% · Top 25%
Revenue growth 3% · Below median
Dividend yield (TTM) 1.0% · Below median
Debt / equity 1.17× · Higher than 75% of peers

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 0.55× · Cheaper than 75% of peers
P/S (TTM) 0.89× · Cheaper than median
P/FCF 2.7× · Cheaper than median
EV/EBITDA 4.2× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 27
FUTURE 13 · sector 23
PAST 5 · sector 29
HEALTH 42 · sector 90
DIVIDEND 19 · sector 41

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Compare OUE LIPPO HEALTHCARE LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is OUE LIPPO HEALTHCARE LTD (5WA) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 0.0862 SGD versus a price of 0.0390 SGD, about +121% (undervalued).
What is the fair value of 5WA?
Our model-based fair value for OUE LIPPO HEALTHCARE LTD is 0.0862 SGD (as of Aug 13, 2026), built from audited fundamentals. The current price is 0.0390 SGD.
What is the quality score of 5WA?
OUE LIPPO HEALTHCARE LTD has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of OUE LIPPO HEALTHCARE LTD (5WA)?
OUE LIPPO HEALTHCARE LTD reported trailing-twelve-month revenue of about 152M SGD (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 5WA?
The net profit margin of OUE LIPPO HEALTHCARE LTD is about -11.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track OUE LIPPO HEALTHCARE LTD and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.